FDA Approves TYENNE — Fresenius Kabi USA, LLC

Fresenius Kabi USA has announced FDA approval of tocilizumab (Tyenne, BLA761275) for the treatment of moderate to severe active rheumatoid arthritis, signaling the company’s continued expansion of its high-growth biologics portfolio. This strategic approval bolsters FDA competition in the rheumatology market and is expected to drive significant commercial revenue growth while leveraging the established patient demand for high-quality tocilizumab products.